Nuo Therapeutics Inc

For the period ended Dec 31, 2023. Filed Apr 19, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 19, 2024

AURXStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

ITEM 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NUO THERAPEUTICS, INC.
Date: April 19, 2024	By:	/s/ David E. Jorden
		David E. Jorden
		Chief Executive and Financial Officer and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Date: April 19, 2024	/s/ David E. Jorden
	David E. Jorden
	Chief Executive and Financial Officer and Director
	(Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)
Date: April 19, 2024	/s/ Paul D. Mintz
	Paul D. Mintz
	Director
Date: April 19, 2024	/s/ C. Eric Winzer
	C. Eric Winzer
	Director
Date: April 19, 2024	/s/ Scott M. Pittman
	Scott M. Pittman
	Director

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Audited Financial Statements
Report of Independent Registered Public Accounting Firm (PCAOB Firm ID No. 688)	F-2
Consolidated Balance Sheets	F-3
Consolidated Statements of Operations	F-4
Consolidated Statements of Changes in Stockholders’ Equity	F-5
Consolidated Statements of Cash Flows	F-6
Notes to Consolidated Financial Statements	F-7

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.